

## **Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024**

TORONTO--(BUSINESS WIRE)--March 5, 2024--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members from Satellos’ management team will host investor meetings at the Leerink Partners Global Biopharma Conference 2024 being held from Monday, March 11 to Wednesday, March 13 in Miami, Florida.

Institutional investors interested in meeting with members of Satellos’s senior management team during the conference may contact their representative at Leerink Partners for further information.

### **About Satellos Bioscience Inc.**

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX<sup>TM</sup>, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit [www.satellos.com](http://www.satellos.com).

### **Contacts**

Investors: Liz Williams, [ir@satellos.com](mailto:ir@satellos.com)

Business Development: Ryan Mitchell, Ph.D., [bd@satellos.com](mailto:bd@satellos.com)

Media: Jessica Yingling, Ph.D., [jessica@litldog.com](mailto:jessica@litldog.com), +1.858.344.8091